|
KMID : 0923620220220050037
|
|
Immune Network
2022 Volume.22 No. 5 p.37 ~ p.37
|
|
|
Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept
|
|
Oh Sang-Wook
Payne Aimee S.
|
|
|
Abstract
|
|
|
|
Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.
|
|
|
KEYWORD
|
|
|
Autoimmunity, Cell therapy, Chimeric antigen receptor, Clinical trials, Pemphigus, Myasthenia gravis, Lupus, Neuromyelitis optica, Systemic sclerosis, Sjogren’s syndrome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|